Johnson & Johnson Announces Opening of London Innovation Centre

       Johnson & Johnson Announces Opening of London Innovation Centre

  PR Newswire

  LONDON, March 13, 2013

-- Centre to Serve as European Hub to Accelerate Innovation across the
Healthcare Landscape

-- Johnson & Johnson Chief Scientific Officer Celebrates Opening at London
Expo Keynote

LONDON, March 13,2013 /PRNewswire/ --Johnson & Johnson today announced the
opening of the Johnson & Johnson Innovation centre in London, one of four
regional hubs being established this year in the world's leading innovation
hotspots. A part of Johnson & Johnson Innovation, the goal of the London
innovation centre is to accelerate the best early stage science in the world
and advance the development of new healthcare solutions. 

"Britain has a worldwide reputation for excellence in innovation - the
investment by Johnson & Johnson here demonstrates this and I am delighted to
welcome this new centre to the UK," says UK Secretary of State for Health
Jeremy Hunt, who will be speaking at the Innovation Expo 2013 on Wednesday.

Johnson & Johnson Chief Scientific Officer and Worldwide Chairman,
Pharmaceuticals, Paul Stoffels, MD, says, "The London Innovation Centre is
part of Johnson & Johnson's broader innovation strategy to advance human
health through collaboration with the world's leading scientists and
entrepreneurs. We are looking forward to collaborating within the UK, home to
one of the world's thriving life sciences ecosystems." Dr. Stoffels will
address the Expo on Wednesday afternoon.

The Johnson & Johnson Family of Companies has been investing in the United
Kingdom since 1927 and supports directly or indirectly more than 24,000 jobs.
The London Innovation Centre will be one of more than a dozen facilities of
the Johnson & Johnson Family of Companies in the country. 

Dr. Stoffels underscores Johnson & Johnson's shared commitment with the NHS to
address some of today's most complex and devastating diseases such as
Alzheimer's, dementia and Type 2 diabetes; and emphasizes the need for
commitment from the healthcare community to support emerging companies and
entrepreneurs in the UK who are bringing forward new science and technology.
"Science and technology hold unprecedented opportunities to transform
healthcare, and by investing and collaborating in groundbreaking science we
can deliver transformational innovations in healthcare to people across the
world."

In addition to the new Johnson & Johnson Innovation centre in London, similar
facilities are planned in Boston, San Francisco and, later this year, in
Shanghai. Each city was selected for its robust life sciences community.

The UK life sciences sector accounts for over 165,000 jobs and over £50
billion in business. It is home to a uniquely powerful combination of
world-leading universities and scientific experts; established R&D,
manufacturing and supply chain; globally renowned research charities and the
NHS. This combination of outstanding features makes London an ideal
innovation hub in Europe.

The Johnson & Johnson Innovation centre in London will house science and
technology experts with broad expertise in developing new solutions and
products. The centre will have local deal-making capabilities to flexibly
adapt deal structures to match early-stage opportunities. This will enable
scientists, entrepreneurs and emerging companies to deliver innovation via
collaboration with experts who can drive partnerships across the
pharmaceutical, medical device & diagnostics and consumer healthcare companies
of Johnson & Johnson.

"Our on-the-ground proximity to regional scientists and entrepreneurs will
allow us to build the strong personal relationships that underlie the most
successful collaborations and investment deals," remarked Patrick Verheyen,
the head of the Johnson & Johnson Innovation centre in London. "At Johnson &
Johnson Innovation, we are committed to ensuring healthcare remains not only a
significant source of economic prosperity in the UK, but also a driving force
for improving the health and happiness of people worldwide."

Johnson & Johnson Innovation centre in London is located at 1 Chapel Place,
London, W1G OBJ. For more information on the new innovation centres please
contact jnjinnovation@its.jnj.com .

About Johnson & Johnson

Caring for the world, one person at a time…inspires and unites the people of
Johnson & Johnson. We embrace research and science – bringing innovative
ideas, products and services to advance the health and well-being of people.
Our approximately 127,600 employees at more than 275 Johnson & Johnson
operating companies work with partners in health care to touch the lives of
over a billion people every day throughout the world.

For more information, visit www.jnj.com .

About J&J Innovation

The London innovation centre is part of Johnson & Johnson Innovation, a
division of Johnson & Johnson Finance Corporation, Ltd. Johnson & Johnson
Innovation focuses on accelerating early innovation and enhancing
opportunities for collaboration and investment across Johnson & Johnson's
global healthcare businesses. Johnson & Johnson Innovation provides
scientists, entrepreneurs and emerging companies focused on early-stage
opportunities a one-stop access to science and technology experts who can
facilitate collaborations across the pharmaceutical, medical device and
diagnostics and consumer companies of Johnson & Johnson. Johnson & Johnson
Innovation includes local deal-making capabilities with the flexibility to
adapt deal structures to match early-stage opportunities and establish novel
collaborations that speed development of those innovations to solve unmet
needs in patients. More information can be found here: www.jnjinnovation.com
.

Forward-looking Statements

(This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. The reader is cautioned not
to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialise, actual results could
vary materially from the expectations and projections of Johnson & Johnson.
Risks and uncertainties include, but are not limited to, general industry
conditions and competition; economic factors, such as interest rate and
currency exchange rate fluctuations; technological advances, new products and
patents attained by competitors; challenges inherent in new product
development, including obtaining regulatory approvals; challenges to patents;
changes in behaviour and spending patterns or financial distress of purchasers
of health care products and services; changes to governmental laws and
regulations and domestic and foreign health care reforms; trends toward health
care cost containment; and increased scrutiny of the health care industry by
government agencies. A further list and description of these risks,
uncertainties and other factors can be found in Exhibit 99 of Johnson &
Johnson's Annual Report on Form 10-K for the fiscal year ended December 30,
2012. Copies of this Form 10-K, as well as subsequent filings, are available
online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson.
Johnson & Johnson do not undertake to update any forward-looking statements as
a result of new information or future events or developments.)

Contact:
Media:              Investors:
Seema Kumar         Stan Panasewicz
+1-908-405-1144      +1-732-524-2524
skumar10@its.jnj.com
Ellen Rose
+1-650-491-4901
erose@janimm.com
Meghan Marschall
+1-201-323-0578
mmarscha@its.jnj.com







Website: http://www.jnj.com
 
Press spacebar to pause and continue. Press esc to stop.